Hepatoma Research

Scope & Guideline

Fostering Collaboration in Liver Cancer Research

Introduction

Welcome to the Hepatoma Research information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Hepatoma Research, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2394-5079
PublisherOAE PUBLISHING INC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 2019 to 2024
AbbreviationHEPATOMA RES / Hepatoma Res.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address245 E MAIN ST, ST122, ALHAMBRA, CA 91801

Aims and Scopes

Hepatoma Research is dedicated to advancing the understanding and treatment of liver cancers, particularly hepatocellular carcinoma (HCC) and cholangiocarcinoma. The journal emphasizes innovative research methodologies that span clinical, translational, and basic science, aiming to improve patient outcomes and treatment modalities.
  1. Hepatocellular Carcinoma (HCC) Research:
    The journal focuses extensively on various aspects of HCC, including its risk factors, molecular mechanisms, treatment strategies, and outcomes, thereby contributing to a better understanding of this prevalent liver cancer.
  2. Cholangiocarcinoma Studies:
    Cholangiocarcinoma, another critical area of focus, is explored through studies that cover its epidemiology, molecular pathology, and treatment advancements, highlighting the need for improved management strategies.
  3. Innovative Treatment Modalities:
    There is a consistent emphasis on novel treatment approaches, including minimally invasive surgeries, radiation therapies, and the use of immunotherapy and targeted therapies, reflecting the journal's commitment to advancing clinical practice.
  4. Multidisciplinary Approaches:
    The journal promotes multidisciplinary research and treatment approaches, integrating perspectives from surgery, oncology, radiology, and pathology to provide comprehensive care for liver cancer patients.
  5. Patient-Centric Research:
    Hepatoma Research also prioritizes research that addresses patient perspectives, quality of life, and real-world outcomes, fostering a holistic understanding of treatment impacts.
The journal has shown a dynamic evolution in its research focus, with several emerging themes gaining significant attention in recent publications. These trends reflect the ongoing advancements in understanding liver cancer and the pursuit of innovative treatment strategies.
  1. Immunotherapy and Checkpoint Inhibitors:
    Recent publications highlight the growing interest in immunotherapy, particularly immune checkpoint inhibitors, as promising treatment options for HCC, reflecting a shift towards harnessing the immune system in cancer treatment.
  2. Minimally Invasive Surgical Techniques:
    There is an increasing trend in research dedicated to minimally invasive surgical techniques for liver cancer treatment, indicating a broader acceptance and application of these approaches in clinical practice.
  3. Molecular and Genetic Profiling:
    Emerging studies focus on the molecular and genetic profiling of liver cancers, which is crucial for the development of personalized medicine strategies and targeted therapies.
  4. Microbiome and Liver Health:
    Recent articles explore the relationship between the gut microbiome and liver diseases, signaling an emerging interest in how microbial health impacts liver cancer development and progression.
  5. Real-World Data and Patient Outcomes:
    An emphasis on real-world data analysis and patient outcomes has emerged, reflecting a growing interest in understanding the effectiveness and impact of treatments in diverse populations.

Declining or Waning

As the field of liver cancer research evolves, certain themes appear to be diminishing in prominence within the journal's recent publications. These waning scopes may reflect shifts in research priorities or advancements in understanding that render previous approaches less relevant.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decline in papers focusing on conventional chemotherapy regimens for liver cancer, as newer targeted therapies and immunotherapies gain traction and demonstrate better efficacy.
  2. Basic Science without Clinical Application:
    Research that solely delves into basic science without a clear translational application seems to be less prominent, indicating a shift towards studies that emphasize clinical relevance and applicability in patient care.
  3. Liver Cancer Surveillance Protocols:
    While surveillance remains crucial, the frequency of studies focused on traditional surveillance protocols has decreased, possibly due to increased emphasis on personalized and risk-based screening strategies.

Similar Journals

Hepatology Communications

Driving discoveries in liver disease and treatment.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: Frequency: 12 issues/year

Hepatology Communications, published by Lippincott Williams & Wilkins, serves as a pioneering platform in the field of hepatology, dedicated to advancing the understanding of liver diseases and treatments. Since its inception in 2017, this open access journal has rapidly gained recognition, achieving an impressive Q1 ranking in Hepatology as of 2023, and appealing to a diverse audience of researchers, clinicians, and students alike. With its focus on high-quality research and clinical studies, the journal aims to facilitate impactful discussions and disseminate vital findings that address the challenges faced in liver health. Operating out of the United States, and accessible globally, Hepatology Communications is committed to fostering a collaborative research environment and enhancing the visibility of scholarly work in hepatology, ultimately driving forward innovations in patient care and treatment strategies.

Therapeutic Advances in Gastroenterology

Leading the charge in gastrointestinal advancements.
Publisher: SAGE PUBLICATIONS LTDISSN: 1756-283XFrequency: 1 issue/year

Therapeutic Advances in Gastroenterology, published by SAGE Publications Ltd, is a premier open access journal dedicated to the advancement of knowledge in the field of gastroenterology. Since its inception in 2008 and its transition to open access in 2018, the journal has consistently provided high-quality peer-reviewed research articles, review papers, and clinical studies that address the latest therapeutic advancements and challenges in gastrointestinal medicine. With an impressive impact factor and a 2023 Scopus ranking placing it in the Q1 quartile of gastroenterology journals, it stands as a leading platform for researchers, clinicians, and healthcare professionals. The journal’s commitment to disseminating impactful research has positioned it at the forefront of academic discourse, offering a vital resource for those devoted to improving patient outcomes in digestive health. The United Kingdom-based journal invites submissions that contribute to the understanding and treatment of gastrointestinal disorders, ensuring that cutting-edge findings reach a global audience.

Chinese Journal of Cancer Research

Pioneering insights into cancer biology and treatment.
Publisher: CHINESE JOURNAL CANCER RESEARCH COISSN: 1000-9604Frequency: 4 issues/year

Chinese Journal of Cancer Research, published by Chinese Journal Cancer Research Co, is a pivotal platform for disseminating significant findings in the field of oncology. Since its inception in 1988, the journal has provided a comprehensive forum for cancer research, featuring peer-reviewed articles that cover various aspects of cancer biology, prevention, diagnosis, and treatment. Although the journal's coverage is currently discontinued in Scopus and holds an HIndex that has not been specified, it is ranked in the 65th percentile in Medicine - Oncology and the 48th percentile in Biochemistry, Genetics and Molecular Biology - Cancer Research. This reflects its commitment to maintaining quality and relevance in the rapidly evolving field of cancer research. Researchers, professionals, and students are encouraged to explore its rich archive of studies and breakthroughs to enhance their understanding and further their research. For access, the publication remains instrumental for those invested in advancing the global fight against cancer.

Clinical and Molecular Hepatology

Advancing liver health through innovative research.
Publisher: KOREAN ASSOC STUDY LIVERISSN: 2287-2728Frequency: 4 issues/year

Clinical and Molecular Hepatology, published by the Korean Association for the Study of Liver, stands at the forefront of hepatology, offering a significant platform for research and innovation in liver diseases. Established in 1995 as an open access journal, it aims to disseminate high-quality research that spans the fields of hepatology, molecular biology, and medicine. With an impressive impact factor ranking it in the Q1 category for 2023 in both Hepatology and Molecular Biology, the journal facilitates a rich exchange of knowledge among professionals, researchers, and students globally. With its dedicated coverage from 2012 to 2024 and exceptional Scopus rankings placing it within the top 10% of journals in its field, Clinical and Molecular Hepatology is an indispensable resource for advancing the understanding and treatment of liver conditions. Located in Seoul, South Korea, the journal emphasizes rigorous peer review and is committed to enhancing clinical practice and molecular research, making it an ideal venue for groundbreaking studies in liver health.

BRITISH JOURNAL OF CANCER

Connecting Researchers and Clinicians in the Fight Against Cancer.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

Hepatic Oncology

Innovating Solutions for Hepatic Malignancies
Publisher: FUTURE MEDICINE LTDISSN: 2045-0923Frequency: 4 issues/year

Hepatic Oncology is a premier Open Access journal published by Future Medicine Ltd that specializes in the critical intersection of hepatology and oncology. With a focus on advancing knowledge in the diagnosis and treatment of liver cancers, the journal provides a platform for innovative research, reviews, and clinical perspectives that serve as a valuable resource for researchers, clinicians, and students alike. Established in 2016 and evolving over the years, Hepatic Oncology underscores its commitment to accessible scientific communication, having transitioned to open access in 2018 to reach a broader audience. The journal holds a Q4 quartile ranking in the fields of hepatology and oncology for 2023, reflecting its emerging influence and role in contemporary research. Through high-quality articles and a focus on real-world applications, Hepatic Oncology aims to bridge gaps in knowledge while fostering collaboration among professionals dedicated to enhancing patient care in hepatic malignancies.

Gastroenterologia y Hepatologia

Empowering healthcare professionals with high-quality research.
Publisher: ELSEVIER ESPANA SLUISSN: 0210-5705Frequency: 10 issues/year

Gastroenterologia y Hepatologia, published by Elsevier España SLU, is a distinguished journal dedicated to advancing the fields of gastroenterology and hepatology. With a publication history spanning from 1982 to 2024, this journal is recognized for its commitment to disseminating high-quality research and reviews that address critical developments in the diagnosis and treatment of gastrointestinal and liver diseases. Although it currently ranks in the Q3 quartile in both gastroenterology and hepatology based on the 2023 metrics, the journal continues to attract a global audience of researchers, healthcare professionals, and students eager to engage with the latest findings. The journal is accessible in both print and electronic formats (ISSN: 0210-5705), making its valuable insights reachable to a broad spectrum of subscribers. By fostering a platform for rigorous scholarly communication, Gastroenterologia y Hepatologia plays a vital role in shaping the future of research in these essential medical fields.

Translational Oncology

Shaping the Future of Oncology Through Discovery
Publisher: ELSEVIER SCIENCE INCISSN: 1936-5233Frequency: 6 issues/year

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

Therapeutic Advances in Medical Oncology

Leading the way in therapeutic oncology advancements.
Publisher: SAGE PUBLICATIONS LTDISSN: 1758-8340Frequency: 1 issue/year

Therapeutic Advances in Medical Oncology, an esteemed journal published by SAGE Publications Ltd, serves as a critical platform for disseminating high-quality research pertinent to the field of oncology. Indexed under the ISSN 1758-8340 and E-ISSN 1758-8359, this Open Access journal has made significant strides since its inception in 2009, attaining a commendable rank of #78 out of 404 in the Medicine - Oncology category of Scopus, placing it in the top 20th percentile of journals. With its category quartile of Q1 established in 2023, it underscores the journal’s commitment to advancing therapeutic approaches in oncology, making it an invaluable resource for researchers, clinicians, and students alike. Offering unrestricted access to pioneering studies since 2017, it aligns with the global movement towards open science, fostering collaboration and innovation among professionals striving to improve cancer treatment outcomes. By bridging the gap between research and clinical practice, Therapeutic Advances in Medical Oncology plays a vital role in shaping the future of cancer therapy.

Journal of Hepatocellular Carcinoma

Exploring innovative solutions for hepatocellular carcinoma.
Publisher: DOVE MEDICAL PRESS LTDISSN: Frequency: 1 issue/year

The Journal of Hepatocellular Carcinoma is a pivotal open-access publication dedicated to advancing the field of hepatocellular carcinoma research. Published by DOVE MEDICAL PRESS LTD since 2014, this journal seeks to disseminate high-quality articles that explore innovative treatments, clinical trials, and emerging research in the context of liver cancer. With its ISSN: N/A and E-ISSN: 2253-5969, the journal is optimized for a global audience, ensuring accessibility to a broad spectrum of researchers, healthcare professionals, and students engaged in oncology and hepatology. While its Scopus ranking places it in the lower quartiles of the respective fields, the journal continues to strive for growth and visibility in a rapidly evolving landscape. The Journal of Hepatocellular Carcinoma is an essential resource for anyone seeking to enhance their understanding of liver diseases and contribute to the fight against hepatocellular carcinoma.